0001021771-26-000068
SEC filingBioRestorative Therapies, Inc. approved cash bonuses for its Named Executive Officers for 2025 services, payable in 2026, as detailed in the updated Summary Compensation Table.
The Compensation Committee approved discretionary cash bonuses for the Company's Named Executive Officers—Lance Alstodt (CEO), Francisco Silva (VP, Research and Development), and Robert Kristal (CFO)—in recognition of their 2025 services. These bonuses, totaling $727,500 across the three executives, are to be paid in 2026 and are reflected in the updated Summary Compensation Table comparing 2025 and 2024 totals. For investors, this disclosure signals alignment of executive incentives with 2025 performance, with total compensation rising notably due to higher salaries, bonuses, and stock/option awards. Stock and option awards represent the grant date fair value under FASB ASC Topic 718.